Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evogliptin vs Pioglitazone for Hepatic Fibrosis in CHB with T2D
NCT04584242Phase 4Unknown
- Sponsor
- Yonsei University
- Start
- Sep 2020
- Primary completion
- May 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of DA5221-B2 in hepatic fibrosis, sponsored by Yonsei University. Status: unknown.
02
Drugs
DA5221-B2
03
Conditions
hepatic fibrosis
Beyond the preview
Go deeper on NCT04584242.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04584242.